Johns Hopkins University
Baltimore, Maryland, 21287, United States
NCT Number: NCT01604356
Retinitis Pigmentosa (RP) patients are interested in trying alternative therapies to attempt to slow, halt or reverse the retinal disease process, and claim success with some approaches such as acupuncture, but this potential treatment has not been put to the test of objective, rigorous scientific study conducted in western society. In this pilot study, the investigators aim to evaluate an acupuncture treatment tailored to the RP population for its feasibility to improve visual function, specifically visual field and dark adaptation. The study results may provide a basis for eye care providers' recommendations to RP patients regarding whether to consider acupuncture as a potential treatment modality. If our hypotheses regarding improvements in vision beyond typical test variability are supported, our future research goals include the conduct of a larger clinical trial with involving randomization and a placebo control for acupuncture in RP.
Looking for future studies?
Notify Me10 year and older
All sexes
Interventional
Phase 1
Baltimore, Maryland, 21287, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
Time frame: initial response within 2 weeks after completion of treatment
Time frame: initial response within 2 weeks of treatment completion
Time frame: initial response within 2 weeks of treatment completion
Time frame: initial response within 2 weeks of treatment completion
Time frame: initial response within 2 weeks of treatment completion
Johns Hopkins University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03374657
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Stockholm, Sweden
View Trial DetailsNCT05282953
Choroid Diseases, Choroideremia
Sydney, New South Wales, Australia
View Trial DetailsNCT05392179
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Durham, North Carolina, United States
View Trial DetailsNCT00378742
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Bethesda, Maryland, United States
View Trial Details